MedTrace Logo

Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial

NCT01600612 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2013-05-31

No results posted yet for this study

Summary

Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality of 140 000 per year. Uterine atony is one of the most important causes of PPH. The traditional treatment of which is the use of uterotonic agents. Oxytocin is the most conventional drug which was proved effective. However, it has the shortcomings of short half life and the necessity of intravenous administration. Misopristol, and more recently Carbetocin were introduced for treatment of atonic PPP not responding to Oxytocin.

Aim of the study is to evaluate the effectiveness of Carbetocin, Misopristol, and Oxytocin for treatment of atonic PPH.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

carbetocin

10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage

DRUG

misopristol

600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage

DRUG

oxytocin

30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage

Sponsors & Collaborators

  • Al-Azhar University

    collaborator OTHER

  • Sohag University

    lead OTHER

Principal Investigators

  • Salah M Rasheed, MD · Department of Obstetrics and Gynecology, Sohag university, Egypt

  • magdy M Amin, MD · Department of obstetrics and Gynecology, Sohag university, Egypt

  • Ahmed H Abd-Ella, MD · Department of obstetrics and Gynecology, Qena university, Egypt

  • Ahmed M Abo Elhassan, MD · Department of obstetrics and Gynecology, Assuit university, Egypt

  • Mazen A El Zahry, M.D. · Department of Obstetrics and Gynecology, Al Azhar university, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-06-30
Completion
2013-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01600612 on ClinicalTrials.gov